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Abstract
Vogt-Koyanagi-Harada (VKH) syndrome is a systemic autoimmune disease. CD4
+ T cells have been shown to be involved in
autoimmune diseases including VKH syndrome. To screen aberrantly expressed membrane proteins in CD4
+ T cell from
patients with active VKH syndrome, blood samples were taken from five patients with active VKH syndrome and five healthy
individuals. A label-free quantitative proteomic strategy was used to identify the differently expressed proteins between the
two groups. The results revealed that the expression of 102 peptides was significantly altered (p,0.05) between two groups
and matched amino acid sequences of proteins deposited in the international protein index (ipi.HUMAN.v3.36.fasta). The
identified peptides corresponded to 64 proteins, in which 30 showed more than a 1.5-fold difference between the two
groups. The decreased expression of CD18 and AKNA transcription factor (AKNA), both being three-fold lower than controls
in expression identified by the label-free method, was further confirmed in an additional group of five active VKH patients
and six normal individuals using the Western blot technique. A significantly decreased expression of CD18 and AKNA
suggests a role for both proteins in the pathogenesis of this syndrome.
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Introduction
Vogt-Koyanagi-Harada (VKH) syndrome is an autoimmune
disorder mainly affecting systemic melanocytes including those in
the eyes, meninges, ears, skin, and hair [1]. It is one of the most
common uveitis entities in China as well as in the Far East of Asia.
The uveitis seen in this syndrome is mostly characterized by a
chronic granulomatous inflammation with recurrent episodes [2].
Although the mechanisms involved in VKH syndrome are not
fully elucidated, previous reports have showed that CD4
+ T cells
sensitive to melanocytes are responsible for the development of
VKH syndrome [3,4]. Recent studies have shown that molecules
related to CD4
+ T cell function, including Fas/FasL [5,6], T-bet
[7], IFN-c, RORct and IL-17 [7,8], are involved in the
pathogenesis of this syndrome. As CD4+ T cells exert their role
principally through a variety of receptors, adhesion molecules,-
transport proteins and costimulatory molecules,which have been
found mainly in the plasma membrane or endomembrane systems,
our study focused on the differentially expressed proteins in the
CD4+ T cell membrane of VKH patients.
Proteomics provides important tools for identifying molecules
involved in both normal and pathological processes [9,10,
11,12,13,14,15]. A recently established label-free strategy [16,17]
has been shown to offer a more robust protein identification and
quantitation, easy automation and large-scale analysis with greater
efficiency as compared to conventional two dimensional electro-
phoresis (2-DE) approaches [18,19,20,21]. In the present study, we
investigated the differentially expressed membrane proteins in
active VKH patients using this label-free proteomic method.
Western blot technique was used to validate the proteomic results.
Our results showed a significantly decreased expression of CD18
and AKNA in CD4
+ T cells from patients with active VKH
syndrome.
Materials and Methods
Clinical Samples
Ten active VKH patients and eleven healthy individuals were
included in the present study. CD4
+ T cells from five active VKH
patients and five healthy individuals were used for label-free
proteomics analysis. CD4
+ T cells from another group of five
active VKH patients and six controls were used for a validation
study.The diagnosis of VKH syndrome was made according to the
criteria revised for VKH syndrome by an international nomen-
clature committee [2]. The patients included in our study had not
been systemically treated with any immunosuppressive agent for at
least one week prior to blood sampling. The mainly clinical
features of VKH patients were shown in Table 1. The healthy
individuals are sex and age matched with VKH patients showing
not any past history of infectious or chronic diseases. An informed
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14616consent (written) was obtained from all patients and the
procedures had been approved by the Ethics Committee of the
First Affiliated Hospital of Chongqing Medical University.
CD4
+ T Cell isolation and flow cytometry
The PBMCs were prepared from heparinized blood by Ficoll-
Hypaque density-gradient centrifugation and were rinsed for three
times in phosphate-buffered saline (PBS). Peripheral CD4
+ T cells
were purified using human CD4 microbeads according to the
manufacturer’s instructions (Miltenyi Biotec, Palo Alto, Calif).
Briefly, PBMCs were suspended in 80 ml of PBS containing 0.5%
bovine serum albumin (BSA) and 2 mM ethylenediamine tetra-
acetic acid (EDTA) per 10
7 total cells. A volume of 20 ml of CD4
microbeads was added to this suspension and incubation was
performed for 15 min at 4uC. The cells were then washed in 2 ml
of PBS containing 0.5% BSA and 2 mM EDTA and applied to a
magnetic column on a MiniMACS separation unit (Miltenyi
Biotec, Palo Alto, Calif). The CD4
+ T cell fraction was collected
and used in subsequent experiments. For flow cytometric analysis,
aliquots of 1610
6 PBMCs and isolated CD4
+ T cells were stained
with PE-cy7-conjugated monoclonal antibody (mAb) against
human CD4 and appropriate isotype controls (eBioscience, San
Diego, CA, USA) for 30 min at 4uC in the dark. Flow cytometric
analysis was performed using FACS Calibur and CellQuest
software (BD Biosciences, SanJose, CA).
Membrane Protein Preparation
Membrane proteins were extracted using a membrane protein
extraction kit (Merck KGaA, Darmstadt, Germany) according to
the manufacturer’s instructions. Briefly, 5610
6 CD4
+ T cells were
pelleted by centrifugation at 300 g for five min. The supernatant
was carefully removed and discarded. Reagent A (150 ml) was
added to the cell pellet and a homogeneous cell suspension was
prepared by pipetting up and down and was then incubated for
10 min at room temperature with occasional vortexing. The lysed
cells were placed on ice. One part of reagent B with two parts of
reagent C were mixed. A total amount of 450 ml of the mixed
reagent B and C was added to each tube of lysed cells and then
vortexed. The tubes were incubated on ice for 30 min with
occasional vortexing. After centrifuging at 10,000 g for 3 min at
4uC, the supernatant was transferred to a new tube and was
incubated for 10 min at 37uC to separate the membrane protein
fraction. The tubes were then centrifuged at room temperature for
2 min at 10,000 g to isolate the hydrophobic fraction from the
hydrophilic fraction. The hydrophilic phase (top layer) was
removed carefully from the membrane-enriched phase (bottom
layer). The protein concentration of the hydrophobic protein was
determined using the protein assay kit (Bio-Rad, Hercules, CA).
The protein was aliquoted and stored at 280uC until use.
Protein Digestion
Protein digestion was performed as follows. The protein
concentration was adjusted to 5 ug/ul with lysis buffer. The
aforementioned membrane protein was chemically reduced for
2.5 h at room temperature by adding DTT to 10 mM, and then
carboxyamidomethylated in 50 mM iodoacetamide for 40 min at
room temperature in the dark. Endoprotease LysC (Roche,
Indianapolis, IN) was added to a final substrate: enzyme ratio of
100:1 (w/w), and the reaction was incubated at 37u for 3 h. The
urea concentration in protein samples was adjusted to 1.5 M with
25 mM NH4HCO3, and then 2 mg of trypsin was added to a final
substrate: enzyme ratio of 50:1 (w/w). The trypsin digest was
incubated at 37u for 20 h. The peptide mixture was acidified by
formic acid to 0.1% for further MS analysis.
Analysis by HPLC and MS
Separation of the trypsin-digested peptides was performed with
the Ettan MDLC system (GE Healthcare, Piscataway, NJ). Peptide
samples were first desalted through a Zorbax 300SB-C18 peptide
traps (Agilent Technologies, Wilmington, DE) and then separated
by a 0.15 mm*150 mm (RP-C18) column (Column Technology
Inc, Fremont, CA) with micro spray mode. An aqueous 0.1%
formic acid solution was used as phase A and a solution of 0.1%
formic acid and 84% acetonitrile was used as phase B. The
Table 1. The clinical features of the investigated patients with VKH disease.
Patient
number Sex Age Ocular Manifestation
Visual
Acuity Extraocular Findings
Mutton-
KPs
Aqueous
cells
Iris
nodules
posterior
synechia
Sunset
glow
fundus
Multiple
peripheral
chorioretinal
lesions od os
Mening-
ismus Tinitus
Alopecia
and
poliosis Vitiligo
Screening
1 Male 33 ++ +++ present present 0.25 0.1 + - ++
2 Male 34 ++++ ++ present present 0.5 0.5 +++-
3 Male 39 ++ ++ present present present 0.08 0.06 - +++
4 Male 24 +++ ++ present present present present 0.06 0.05 +++-
5 Female 34 ++ ++ present present present 0.8 1.0 - +++
Validation
6 Male 18 ++ ++ present present 0.7 0.6 - ++-
7 Female 27 ++ +++ present present present 0.6 0.01 + - + -
8 Female 50 ++ ++ present present present 0.3 0.05 +++-
9 Male 46 ++ +++ present present 1.0 0.8 - +++
10 Male 41 +++ ++ present present present present 0.2 0.5 ++++
doi:10.1371/journal.pone.0014616.t001
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phase B over 2 hours at a flow rate of 1300 nl/min. The column
temperature was maintained at 170 uC.Both pooled samples were
analyzed in triplicate.
The separated peptides were analyzed on a Finnigan LTQ
linear ion trap mass spectrometer (Thermo Finnigan, San Jose,
CA) equipped with a nanoelectrospray ion source [16,17]. The
injection voltage was set to 3.0 kV and the normalized collision
energy was set to 35.0. The number of ions stored in the ion trap
was regulated by the automatic gain control. Each scan cycle
consisted of one full scan mass spectrum (m/z 0,1600) collected
in profile mode. Five MS/MS events were recorded in centroid
mode with the dynamic exclusion settings: repeat count 2, repeat
duration 30 s, exclusion duration 90 s. MS/MS spectra were
searched against the IPI human protein database (version 3.36;
69012 entries) and analyzed using SEQUEST of BioworksBrowser
rev. 3.1. The search was performed with one missed cleavage
permitted. The fixed and variable modifications were set to
Carbamidomethyl (C) and oxidation (M) respectively. The mass
tolerance for precursor ions was set to 3.0 Da. The mass tolerance
for fragment ions was set to 1.0 Da. The peptide matches were
filtered based on cross-correlation scores (Xcorr) of 1.9, 2.2 and
3.75 for charge states 1+,2 +, and 3+, respectively. All the peptides
with different charges were translated to single charge and
expressed as ‘‘MH+’’ (Supplemental Table 1). To determine the
false discovery rate (FDR), the data set was searched against a
sequence-reversed decoy IPI human version 3.36 database using
the same search parameters. FDR was calculated using the
formula reported by Xue et al [17]: FDR= Number of false
peptides/(Number of true peptides+Number of false peptides)
6100%.
Label-free Detection and Quantitation of Peptides
The peaklist of peptides was generated using DeCyder MS
software version 1.0 (GE Healthcare, Piscataway, NJ) and the
quantitative analysis of peptides was performed. Peptide detection,
elution profile comparison, background subtraction and peptide
quantitation were carried out on the full scan precursor mass
spectra in fully automatic mode. Peptide quantitation is based on
MS signal intensities of individual LC-MS analyses. Different
signal intensity maps were matched using the pepmatch module
and then the peptide quantitative results were acquired. As there
was no internal standard, the intensity distributions for all peptides
detected in both samples were used for normalization. Throughout
these studies the mass tolerance in the software was set to 0.5
atomic mass unit and the retention time tolerance was set to
2 min.
Western blot analysis
Total protein of CD4
+ T cells from five active VKH patients and
six healthy individuals were prepared for Western blot analysis. Ten
micrograms of protein from each specimen were used for SDS-
PAGE. The gels were then transferred to a PVDF membrane.
Membranes were incubated with antibodies at dilutions of 1:1000
for both anti-human CD18 mAb (R&D systems, Minneapolis, MN)
and anti-human AKNA mAb (Genway Biotech, San Diego, CA).
Proteins were detected using the Phototope-HRP western blot
detection system (Cell Signaling, Danvers, MA).
Statistical analysis
For differential analysis of peptides from both VKH patients
and normal controls, student’s t-test was performed using the
Decyder MS software. A p-value of less than 0.05 was considered
as a significant difference. In the validation study, the immunoblot
bands were quantified using Bio-rad quantity one 1-D analysis
software. Band density was normalized to that of an internal
control, b-actin. The differences of immunoblot band intensities
between both groups were analyzed by student’s t-test using SPSS
software (version 13.0). A p-value of less than 0.05 was considered
as statistically significant.
Results
CD4
+ T cell isolation
CD4
+ T cells were sorted from peripheral blood of ten active
VKH patients and eleven healthy individuals using CD4 microbe-
ads. The purity of CD4
+ T cells identified in both patients and
controls was 98% (Figure 1). The obtained CD4
+ T cells from both
groups were subjected to label-free quantitative proteomic analysis
followed by Western blot validation.
Figure 1. Representative flow cytometric map of CD4
+ T cells isolated from peripheral blood of active VKH patients. The PBMC and
freshly isolated CD4
+ T cells were stained with the indicated markers using fluorescence-labeled mAb and analyzed by flow cytometry. Before sorting,
the ratio of CD4
+ T cells in PBMC was 38.11% (A). After microbeads based sorting, the purity of CD4
+ T cells was as high as 98.06% (B).
doi:10.1371/journal.pone.0014616.g001
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Before conducting the relative protein profiling analysis between
the two pooled samples from VKH patients and normal controls,
several quality control measures were performed on the replicates
of both pools to determine analytical reproducibility. The mass
precision of the extracted peptide components was within 5 parts
per million (ppm) of mass error. The quality control analysis
revealed similar results between patients and controls concerning
the median and average mass errors (1.90 vs 2.80 ppm), intensity
errors (2.10% vs 1.95%), and retention time (0.70% vs 0.50%).
Reproducibility between duplicate runs was evaluated using a
binary comparison map. The horizontal (x) axis represents the
distribution of peak intensities of the first run, and the vertical (y)
axis represents that of the second run. The average intensity
correlation coefficient (CC) between the two runs was 0.92. A
representative binary comparison map is shown in Figure S1. The
expected distribution of the duplicate runs showed no obvious
change. These quality control measurements were performed on
all runs and both experimental pools.
Relative quantitation of peptides in total membrane
protein extracts
The digested membrane proteins of CD4
+ T cells prepared
from active VKH patients and normal controls were analyzed by
LC-MS/MS. Base peak ion chromatograms were acquired in
profile mode to get enough data points for evaluation by DeCyder
MS. A representative base peak ion chromatogram from the
analysis of the VKH pool is shown in Figure S2. The other runs
displayed similar profiles. The MS files were converted to signal
intensity maps, 2-D representations with m/z on the y axis and
retention time on the x axis. A representative intensity map
(CD18) is shown in Figure 2, A and B. The density of the grayscale
pattern was proportional to the signal intensity of a peptide peak at
a certain m/z, retention time, and charge state. The signal
intensity maps were analyzed using the PepDetect module of
DeCyder MS to detect and quantitate the peptide ions. Since each
sample was analyzed in triplicate, peptides from six signal intensity
maps were matched and analyzed. As the peptide content reflects
the protein level, relative quantitation for corresponding proteins
Figure 2. Decyder MS intensity graphs of CD18 derived from LC-MS/MS analysis of a total membrane protein extracted from both
normal group (A) and VKH group (B). The location of peptide ALNEITESGR in both samples was labeled with square frames in the total graphs
and the magnified graphs (C and D). Statistical analysis showed that the different expression of peptide ALNEITESGR was significant between VKH
group and normal group (E).
doi:10.1371/journal.pone.0014616.g002
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0.05 was used as a threshold to identify significantly up- or down-
regulated expression. The MS/MS data was collected in centroid
mode and was transferred to TurboSEQUEST software for
protein identification.
In total 354 peptides were identified to be significantly different
between both groups, in which 102 could be sequenced and which
corresponded to 64 proteins. A FDR of 3.77% at the peptide level
was obtained by searching against the sequence-reversed decoy IPI
human database, suggesting a high fidelity of this strategy. Thirty
proteins showed a difference of at least 1.5-fold, when comparing
active VKH patients with normal controls. Of these, eight proteins
were identified based on two or more unique peptides (Table 2)
and in 22 the identification was based on a single peptide (Table 3).
All the identified peptides and their sequences of each protein in
both samples are listed in the Table S1. For single-peptide-based
identifications, the MS/MS spectra appropriately labeled were
listed in Figure S3.
Validation of CD18 and AKNA by Western blot technique
Among the thirty proteins identified, two proteins, CD18 and
AKNA, were found to have a more than three-fold difference
between active VKH patients and normal controls. The different
expression of CD18 in both samples was shown in magnified
intensity graphs (Figure 2, C and D). Our study further validated
the expression of these two proteins using the Western blot
technique. The immunoreactive band intensities were quantitated
and were presented as intensity volumes (vol %). The results
showed that the expression of CD18 was about five-fold lower in
the active VKH patients as compared to normal controls. As for
the expression of AKNA, a similar result was observed (Figure 3).
The results for both proteins were generally consistent with the
quantitative data of the label-free method.
Discussion
In this study, label-free relative quantitative proteomics was
employed to screen differently expressed membrane proteins in
CD4
+ T cells from active VKH patients and normal controls.
Thirty proteins were identified to be at least 1.5 fold differently
expressed between active VKH patients and normal individuals. A
significantly decreased expression of CD18 and AKNA was
further confirmed using the Western blot technique. The results
presented here may provide new clues for the study on molecules
involved in the pathogenesis of VKH syndrome.
CD4
+ T cells have been shown to be crucial in the pathogenesis
of this syndrome [5,6,22]. The present study aimed at searching
for the differently expressed proteins in these cells between active
VKH patients and normal controls. Proteomics has provided
useful strategies for the screening of differently expressed proteins.
The recently established label-free strategy has been proven to be
more efficient as compared to conventional 2-DE approaches
[18,19,20,21]. It has been used to identify urinary biomarkers
from antineutrophil cytoplasmic antibodies [23] and differently
expressed proteins from patients with ductal carcinoma [24] and
Parkinson’s disease [25]. These studies have proven that the label-
free strategy is a powerful tool for identifying disease-associated
proteins. In this study, we employed the label-free approach to
identify differently expressed proteins in CD4+ T cells, an
important population involved in various autoimmune diseases,
between active VKH patients and normal controls.
To ensure the accuracy and stability of the label-free
quantitative analysis, several procedures were performed. For
the purpose of minimizing the effect of individual differences on
the experimental results, an equal amount of membrane proteins
of CD4+ T cells from five active VKH patients and five normal
controls were pooled respectively and subjected to the label-free
quantitative proteomics. For label-free proteomics, strategies using
three or four technical replicates have been reported [16,17,26].
As three technical replicates are a minimal requirement for
statistical analysis and have already been justified by a number of
studies, we chose three technical replicates in the present study.
Our results showed a great reproducibility in peptide quantitation
(Table S1). To acquire stable MS data needed for quantitative
analysis, several quality control measures were used [16]. The data
from each run of both VKH patients and normal controls
appeared to be reproducible in terms of mass accuracy, retention
time and intensity. Binary comparison maps used in the
experiment validated the reproducibility between duplicates.
Coefficient of variation (CV) analysis [17] was performed and
the result showed that the average CV of the fold changes was
23% for proteins with two or more peptides, which ensured the
accuracy of protein quantitation (Table S2).
Our label-free proteomic results showed that thirty proteins
were different in expression for more than 1.5 fold between active
VKH patients and normal controls,although these results need to
be confirmed by other techniques. By searching for the functions
of these proteins according to annotations in the Swiss-prot
database at http://expasy.org, we interestingly noted that these
identified proteins are involved in 54 biological processes (Table
S3) and 39 functional groups (Table S4). Importantly, we found
that a number of molecules, including vimentin, dystrophin,
Keratin 10, AKNA and CD18, are associated with an inflamma-
tory and/or immune response. An abnormal expression of certain
proteins has also been found to be involved in autoimmune
diseases or immune related diseases [27,28,29]. Enhanced
vimentin immunoreactivity was found in the spinal cord of rats
with experimental autoimmune encephalomyelitis [28]. Increased
expression of dystrophin was observed in experimental autoim-
mune myasthenia gravis [27].
By analyzing the data acquired using the label-free method, it
was interesting to note that a number of proteins identified in this
study, including vimentin and AKNA transcription factor, were
non-membrane components. A similar result has also been
observed in proteomic studies. These non-membrane molecules
could be explained as being a component associated with the
membrane or with membrane fractions [30,31]. It is worthy to
point out that the increased expression of keratins may be
involved in the pathogenesis of a number of diseases affecting the
skin [32,33,34,35]. It is not clear whether keratins are truly
induced and, if it is, how it functions in VKH syndrome, an
autoimmune disease frequently affecting the integumentary
system.
False positive data always exist in proteomic studies. Therefore,
the proteomic results usually need to be confirmed using other
techniques. As protein with a big different expression ratio is
readily confirmed by another technique, we chose two proteins
with a three-fold different expression between VKH patients and
normal controls, CD18 and AKNA, as candidates in the
Westernblot identification. As expected, the Western blot result
revealed a five-fold lower expression of both proteins in active
VKH patients as compared with normal controls. It is worthwhile
to point out that both CD18 and AKNA were identified using the
one peptide based identification, as already reported previously
[36,37]. This could be due to the lower abundance of both
proteins in the tested samples.
CD18, also known as integrin beta 2 or ITGB2, is one of the
members of the integrin family, which is involved in cell adhesion,
Proteomics in VKH Syndrome
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expression of CD18 can be down-regulated by introducing an
insertion mutation in the murine CD18 gene. Due to this
mutation, a chronic inflammatory skin disease clinically resem-
bling human psoriasis develops in PL/J mice [38,39]. It has been
reported that resistance of T cells to apoptosis may be involved in
Table 2. The differently expressed proteins identified based on two or more peptides in CD4
+ T cells between active VKH patients
and normal individuals.
Gene
symbol
Swiss-prot
accession No.
Identified
proteins
Expression
Ratio
a
(VKH:NC) Xcorr
b t-test p MH+ (Da)
Mass
stdev
(Da) Identified Peptide
Up-regulated in VKH
VIM B0YJC4 Vimentin 2.8 2.42 0.00004 1060.7690 0.08313 159 R.QVDQLTNDK.A 169
5.53 0.00002 1169.9804 0.11453 129 K.ILLAELEQLK.G 140
2.27 0.00061 1428.8390 0.13478 50 R.SLYASSPGGVYATR.S 65
3.16 0.00031 1115.8539 0.14490 105 K.VELQELNDR.F 115
3.36 0.00032 1323.8875 0.13155 196 R.EEAENTLQSFR.Q 208
3.99 0.00045 1406.1375 0.30727 223 K.VESLQEEIAFLK.K 236
3.30 0.00030 1533.9759 0.26803 222 R.KVESLQEEIAFLK.K 236
3.30 0.00029 1312.8985 0.35813 207 R.QDVDNASLAR.L 218
2.26 0.00061 1226.9591 0.20369 294 K.FADLSEAANR.N 305
KRT10 P13645 Keratin, type I
cytoskeletal 10
2.0 2.26 0.00449 993.8803 0.14940 237 K.YENEVALR.Q 246
2.49 0.00409 1435.8816 1.01701 439 K.IRLENEIQTYR.S 451
3.40 0.00108 2083.0051 0.17698 422 R.AETECQNTEYQQLLDIK.I 440
2.27 0.02983 1262.8610 0.14280 450 R.SLLEGEGSSGGGGR.G 465
3.03 0.00403 1031.5372 0.57250 257 R.VLDELTLTK.A 267
3.84 0.00012 1494.0186 0.19081 322 R.SQYEQLAEQNRK.D 335
2.26 0.00448 1236.916 0.16415 165 R.ALEESNYELEGK.I 178
ATP5B P06576 ATP synthase subunit
beta, mitochondrial
precursor
1.8 2.26 0.00433 1988.1477 0.17359 387 R.AIAELGIYPAVDPLDS
TSR.I 407
3.57 0.00622 975.7282 0.15882 201 K.IGLFGGAGVGK.T 213
2.67 0.00022 1088.6165 0.50286 188 K.VVDLLAPYAK.G 199
ACTA2 P62736 Actin, aortic smooth
muscle
1.8 3.83 0.01604 1354.8744 0.12513 52 K.DSYVGDEAQSKR.G 65
3.12 0.00290 1198.7264 0.08676 52 K.DSYVGDEAQSK.R 64
KRT2 P62736 Keratin, type II
cytoskeletal 2 epidermal
1.8 4.91 0.00099 1191.8102 0.09092 374 K.YEELQVTVGR.H 385
4.89 0.00012 1461.0514 0.45310 302 K.VDLLNQEIEFLK.V 315
3.95 0.00025 1372.6575 0.48309 441 K.LNDLEEALQQAK.E 454
KRT1 P04264 Keratin, type II
cytoskeletal 1
1.6 2.24 0.00899 993.8803 0.14940 443 K.LNDLEDALQQAK.E 456
4.70 0.00027 1435.8816 1.01701 343 R.SLDLDSIIAEVK.A 356
3.08 0.00072 2083.0051 0.17698 185 K.SLNNQFASFIDK.V 198
ALB A6NBZ8 Uncharacterized
protein ALB
1.6 2.95 0.04948 1444.1611 0.54524 286 K.YICENQDSISSK.L 299
3.08 0.00704 1512.1173 0.04618 438 K.VPQVSTPTLVEVSR.N 453
2.95 0.04947 1078.9591 0.10821 499 K.CCTESLVNR.R 509
Down-regulated in VKH
SFRS1 Q07955 Isoform ASF-1 of
Splicing factor, arginine/
serine-rich 1
0.50 2.52 0.00007 1255.5932 0.37017 17 R.IYVGNLPPDIR.T 29
2.78 0.03060 1078.9591 0.10822 154 R.DGTGVVEFVR.K 165
3.37 0.00126 1417.7458 0.11825 142 R.EAGDVCYADVYR.D 155
a: average expression ratio;
b: cross-correlation score.
doi:10.1371/journal.pone.0014616.t002
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has been shown to be required in apoptosis of human T cells
[40,41,42]. A decreased expression of CD18 in active VKH
patients may suggest that an insufficient inhibition on apoptosis of
CD4
+ T cells is present at the active stage.
ANKA, also known as AHCTF1, is reported to regulate the
expression of CD40 and CD40L [43], both molecules essential in
immune and inflammatory responses. The interaction of CD40
and CD40L has been shown to be involved in the negative
regulation of T cell autoreactivity and abnormalities in their
interaction may lead to autoimmunity. In the present study, a
significantly decreased expression of AKNA was noted in CD4
+ T
cells from active VKH patients. The decreased AKNA may be
presumed to down-regulate the expression of CD40L in CD4
+ T
cells. Such a decreased expression of CD40L has indeed been
observed in peripheral CD4
+ T cells in autoimmune thyroid
disease [44]. More studies are needed to clarify whether a
decreased AKNA could play a role in VKH syndrome via down-
regulating CD40 and CD40L.
In summary, label-free quantitative proteomics showed
abnormal expression of thirty proteins for more than 1.5 fold
in active VKH patients. A significantly decreased expression of
CD18 and AKNA was confirmed using the Western blot
technique. Both proteins may be involved in the pathogenesis of
VKH syndrome. However, our study did not elucidate the
mechanism by which both proteins exert their function. Further
studies about the effect of both proteins on cytokine expression,
apoptosis and chemotaxis of CD4
+ Tc e l l sw i l lc o n t r i b u t et oo u r
understanding about the mechanisms in the pathogenesis of
VKH syndrome.
Table 3. The differently expressed proteins identified based on single peptides in CD4
+ T cells between active VKH patients and
normal individuals.
Gene
symbol
Swiss-prot
accession
No. Identified proteins
Expression
Ratio
a
(VKH:NC) Xcorr
b t-test p
MH+
(Da)
Mass
stdev
(Da) Identified Peptide
Up-regulated in VKH
ITGB2 (CD18) A8MYE6 Integrin beta 2.9 3.66 0.00068 1047.7857 0.11764 520 R.TTEGCLNPR.R 530
ODZ3 Q9P273 Teneurin-3 2.5 4.03 0.00004 2254.3396 0.17867 897 R.QDGMFDLVANGGASLTL
VFER.S 920
CORO2A Q92828 Coronin-2A 2.4 2.21 0.00128 1550.6224 0.22761 235 K.KLMSTGTSRWNNR.Q 249
C19orf2 Q8TC23 C19orf2 protein 2.3 2.91 0.01076 1088.1358 0.47804 344 R.INTGKNTTLK.F 355
DMD P11532 Isoform 4 of Dystrophin 2.1 4.05 0.00033 1226.9591 0.20370 602 K.LAVLKADLEKK.K 614
SYCP2 Q9BX26 Synaptonemal complex protein 2 2.1 3.18 0.00454 1427.8801 0.06260 509 R.IKPPLQMTSSAEK.P 523
DKFZp686D0972 Q562R1 hypothetical protein LOC345651 1.9 2.27 0.00140 1791.0197 0.11971 239 R.SYELPDGQVITIGNER.F 256
CDNA FLJ41329
fis, clone
BRAMY2047676
Q6ZWC4 none 1.9 3.05 0.00548 1546.8087 0.08170 107 R.ALNLGAATVLRRHR.A 122
SLC22A11 Q9NSA0 Isoform 1 of Solute carrier
family 22 member 11
1.9 2.63 0.00783 2210.0904 0.46292 301 R.INGHKEAKNLTIEVLMSS
VK.E 322
RPS27A P62979 UBC;UBB ubiquitin and ribosomal
protein S27a precursor
1.8 3.39 0.01933 1788.1465 0.15637 11 K.TITLEVEPSDTIENVK.A 28
ARL6IP5 O75915 PRA1 family protein 3 1.8 2.85 0.00053 1312.8985 0.35814 9 R.AWDDFFPGSDR.F 21
ACTB P60709 Actin, cytoplasmic 1 1.8 4.57 0.00029 1132.7391 0.08870 196 R.GYSFTTTAER.E 207
GPR179 A8MWI1 Probable G-protein coupled
receptor 179 precursor
1.7 4.26 0.00002 1150.9204 0.12430 2099 R.GSSEAAGSVETR.V 2112
HSPA9 P38646 heat shock 70kDa protein 9,
mitochondrial precursor
1.7 4.66 0.04236 1450.7788 0.13564 85 R.TTPSVVAFTADGER.L 100
FAM62A Q9BSJ8 Isoform 1 of Protein FAM62A 1.6 2.68 0.02300 1402.3521 0.45065 106 R.QLLDDEEQLTAK.T 119
ELMO2 Q7Z5G9 ELMO2 protein 1.6 3.18 0.01234 1484.9090 0.09548 1 MERTQSSNMETR.L 13
CCDC73 Q6ZRK6 Isoform 1 of Coiled-coil
domain-containing protein 73
1.6 2.39 0.01896 1583.8480 0.08212 84 K.EAMAVFKKQLQMK.M 98
Down-regulated in VKH
PRPH P41219 Isoform 1 of Peripherin 0.60 2.88 0.01008 1309.9330 0.17343 398 K.LLEGEESR.I 407
ATP5A1 P25705 ATP synthase subunit alpha,
mitochondrial precursor
0.60 2.54 0.00232 1316.9060 0.22248 218 K.TSIAIDTIINQK.R 231
CANX B4DGP8 Calnexin precursor 0.37 2.70 0.00003 1488.7949 0.25015 480 R.IVDDWANDGWGLK.K 494
AKNA Q7Z591 Isoform 1 of AT-hook-
containing transcription factor
0.33 3.75 0.00007 1236.9160 0.16416 330 R.PLPRQGATLAGR.S 342
ITGB2(CD18) P05107 Integrin beta-2 precursor 0.24 2.54 0.00017 1090.0657 0.37385 155 R.ALNEITESGR.I 166
a: average expression ratio;
b: cross-correlation score.
doi:10.1371/journal.pone.0014616.t003
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Figure S1 A representative binary comparison map of duplicate
runs of samples from VKH patients. The horizontal (x) axis
represents the distribution of peak intensities of the first run, and
the vertical (y) axis represents that of the second run. The average
intensity correlation coefficient (CC) between the two runs was
0.92. The expected distribution of the duplicate runs showed no
obvious change.
Found at: doi:10.1371/journal.pone.0014616.s001 (0.04 MB
PDF)
Figure S2 A representative base peak ion chromatogram from
LC-MS/MS analysis of a total membrane protein extract from the
VKH group digested with trypsin.
Found at: doi:10.1371/journal.pone.0014616.s002 (0.19 MB
PDF)
Figure S3 The MS/MS spectra for single-peptide-based iden-
tifications. The detected b and y ions used in the protein
identification were labeled in the MS/MS spectra. The unlabeled
peaks are a, c, x or z ions generated in mass spectrometer.
Found at: doi:10.1371/journal.pone.0014616.s003 (1.88 MB
PDF)
Table S1 All the identified peptides and their sequences of each
protein in both samples.
Found at: doi:10.1371/journal.pone.0014616.s004 (0.08 MB
XLS)
Table S2 C.V.analysis of all the identified proteins based on at
least two peptides.The average CV of the fold changes was 23%
for proteins with two or more peptides.
Found at: doi:10.1371/journal.pone.0014616.s005 (0.06 MB
XLS)
Table S3 Biological Process of the identified proteins.
Found at: doi:10.1371/journal.pone.0014616.s006 (0.02 MB
XLS)
Table S4 The molecular function of the identified proteins.
Found at: doi:10.1371/journal.pone.0014616.s007 (0.08 MB
XLS)
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